<DOC>
	<DOCNO>NCT02283242</DOCNO>
	<brief_summary>It recognize inflammation modulate cholinergic stimulation galantamine , inhibitor acetylcholinesterase enzyme central nervous system action , show anti-inflammatory effect , reduce body weight , abdominal fat improvement tissue insulin resistance animal model . Galantamine safe drug use treat alzheimer disease.Galantamine treatment patient metabolic syndrome may represent significant advance management disease . This study aim investigate effect galantamine inflammatory marker , well abdominal visceral epicardial fat oxidative stress patient metabolic syndrome . This pioneering study include expert support . The enrol subject continuous monitor throughout period treatment . The study double blind randomized prospective study 60 patient metabolic syndrome , randomize ratio 1 : 1 placebo galantamine . The dose galanthamine standard clinically approve ( 8 16 mg ) . The track method include metabolic analysis , inflammatory oxidative stress marker , hemodynamic evaluation hear rate variability ( sympatho vagal modulation ) , treatment . Computerized tomography assessment visceral abdominal epicardial fat treatment perform .</brief_summary>
	<brief_title>Galantamine Effects Patients With Metabolic Syndrome</brief_title>
	<detailed_description>Population : patient metabolic syndrome ; Intervention : Galantamine ; Comparation : Placebo ; Outcomes ( primary ) : proinflammatory cytokine level . Description : Patients criteria Metabolic Syndrome ( 2005 revise NCEP ATP III criterion ) randomize 2 group : use galantamina ( 30 patient ) placebo ( 30 patient ) follow sequency : I ) 4 week treatment 8 mg galantamine placedo ( oral ingestion capsule ) ; II ) 8 week treatment 16 mg galantamine placebo ( oral ingestion capsule ) . Participants receive diary record symptom may present instructed bring study visit . Before randomization participant go follow procedure : - Clinical neurological evaluation ; - Blood sample analysis cytokine , oxidative stress biochemical parameter ; - Multidetector compute tomographic ( MDCT ) scan abdomen ( visceral - abdominal epicardial fat ) thorax ( calcium score ) ; - blood pressure record hemodynamic evaluation assessment heart rate variability - 24h ambulatory blood pressure measurement These procedure repeat end protocol . This randomize control trial study . Blinding status : Patients , investigator , outcome assessor . All participant outpatient . The invitation participate study detail protocol explain . Once patient criterion inclusion , receive card capsule contain placebo galantamine accord continuous numerical order provide pharmacy prepared randomize substance ( numbered container ) . Drug placebo manipulate encapsulated identical packaging Central Pharmacy School Medicine , University São Paulo . We use simple randomisation use randomisation table create computer software - graphpad Software- quickcalcs .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Obesity , Abdominal</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Cholinergic Agents</mesh_term>
	<criteria>Inclusion : Diagnosis Metabolic Syndrome base recently establish criterion ( three abnormal finding follow five ) Increased abdominal circumference ≥ 102 cm men 90 cm woman Low plasma level HDL cholesterol &lt; 40md/dL men 50 mg/dL woman Increased value plasma triglyceride &gt; 150 mg/dL Elevated blood pressure ≥130/85 mmHg Elevated level blood sugar value 100 mg/dL Body Mass Index ( BMI ) 25 39 , weight maintenance diet stable least 6 month study entry Normal renal function thyroid function Able participate study signing inform consent form comply study stage throughout duration Exclusion : On use antidiabetic medication Triglyceride level ≥ 400 mg/dL use lipid lower medication Levels aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≥ 200 U/L Levels aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≥ 200 U/L The office systemic blood pressure ≥160 mmHg diastolic blood pressure ≥110 mmHg rest BMI ≥ 40kg/m² In use antihypertensive drug interfere heart rate variability On use drug know probable interaction galantamine : amitriptyline , fluoxetine , fluvoxamine , ketoconazole , oxybutynin , paroxetine , quinidine Already participant regular exercise program , define 90 minute activity per week Medical history , previous diagnosis previous supplementary examination indicate presence cardiac arrhythmia , coronary artery disease , valvular disease , heart failure , chronic obstructive pulmonary disease , acute chronic liver disease , renal insufficiency , thyroid disorder , chronic inflammatory disease , cancer , positive status HIV , debilitate disease Abuse alcohol substance 12 month prior study entry History major depression patient suicidal ideation Personal history eat disorder Utilization drug obesity Use serotonin reuptake inhibitor Pregnancy desire become pregnant study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cholinergic Antagonists</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Oxidative Stress</keyword>
</DOC>